ArticleFrontiers in psychiatry2025
Clomipramine potentially induced fatal torsades de pointes in a patient with acute decompensated heart failure: a case report.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of anti-anxiety therapy on the prognosis of patients with atrial fibrillation and anxiety: a 2 × 2 factorial randomized controlled trial.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While clomipramine is generally considered lower risk for QT prolongation among tricyclic antidepressants, its potential to induce torsades de pointes (TdP) remains poorly characterized, particularly in patients with multiple risk factors. Case presentation: A 78-year-old male with a history of hypertension, atrial fibrillation, and post-stroke depression presented to the emergency department with a one-week history of chest distress. Initial evaluation revealed atrial fibrillation with a prolonged QTc interval of 550 ms on electrocardiogram (ECG) monitoring, and elevated B-type natriuretic peptide (1130 pg/mL). The patient was admitted for acute decompensated heart failure and treated with torasemide intravenously while continuing clomipramine (25 mg daily) for depression. Within 24 hours, he experienced multiple episodes of torsades de pointes (TdP), coinciding with hypokalemia (serum potassium: 3.21 mmol/L). Despite corrective measures, including potassium and magnesium supplementation, the patient developed ventricular fibrillation and cardiac arrest, leading to death. Conclusion: This case highlights the potential risk of clomipramine-induced QT prolongation and TdP, particularly in patients with acute heart failure and electrolyte imbalances, underscoring the need for careful risk assessment and monitoring in such populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.